




National Prostate Cancer Audit State of the Nation Report 2026 – Appendix

An audit of care received by people diagnosed or treated with prostate cancer between 1 January 2015 and 31 December 2025 in England and Wales.

Published October 2026



1. Acknowledgements

In July 2023, the NPCA moved into the National Cancer Audit Collaborating Centre (NATCAN) at the Clinical Effectiveness Unit (CEU) of the Royal College of Surgeons of England. NATCAN is a new national centre of excellence to strengthen NHS cancer services by looking at treatments and patient outcomes across the country. The new centre is commissioned by the Healthcare Quality Improvement Partnership (HQIP) on behalf of NHS England and the Welsh Government as part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP).

The audit is a collaboration between the Clinical Effectiveness Unit (CEU) at the Royal College of Surgeons of England (RCS), the British Association of Urological Surgeons (BAUS) and the British Uro-oncology Group (BUG). We would like to thank BAUS and BUG for their continued professional guidance and for raising awareness amongst urological and uro-oncological colleagues.

We would also like to thank all urologists, uro-oncologists and their clinical and non-clinical teams at NHS Trusts in England and Health Boards in Wales who collected and submitted data for the audit. Your support is key to enabling the NPCA to evaluate the care that men receive following a diagnosis of prostate cancer in England and Wales and whether this care reflects recommended guidelines and quality standards.

The NPCA compares NHS Providers in England and Wales and provides these results to underpin quality improvement activities. We are grateful to the National Cancer Registration and Analysis Service (NCRAS) which is part of the National Disease Registration Service, NHS England (NHSE) and the Wales Cancer Network, Public Health Wales for supporting routine cancer data submissions from Trusts and Health Boards and for supplying data for this report. We particularly appreciate the efforts of the cancer intelligence analysts and cancer information specialists at NCRAS and the Wales Cancer Network who supplied the data during the COVID-19 pandemic.

We would also like to thank all members of the NPCA Patient and Public Involvement (PPI) Forum for providing advisory support and ensuring the voice of patients is central to the direction and delivery of the NPCA. A lay report summarising the key results has been developed in consultation with the NPCA PPI Forum and is published simultaneously.

2. Supplementary tables: national results

Table A1. The number of men (and proportion of total for that year) with prostate cancer starting different types of systemic therapy regimens within 16 weeks of diagnosis in England, from 1st January 2019 to 31st May 2025.

	Abi		Apa		Doce		Enza		Daro		Daro+Doce		Total	
2019	13	<1%	0	0%	2,036	99%	7	0.3%	0	0%	0	0%	2,056	100%
2020	79	4%	<5	<1%	993	46%	1,108	51%	0	0%	0	0%	2,181	100%
2021	154	5%	110	3%	1,029	32%	1,884	59%	0	0%	0	0%	3,177	100%
2022	83	3%	719	24%	1,062	35%	1,189	39%	0	0%	<5	<1%	3,056	100%
2023	107	3%	974	29%	760	23%	1,106	33%	55	2%	314	9%	3,316	100%
2024	282	7%	1101	28%	640	16%	1,204	31%	81	2%	600	15%	3,908	100%
2025*	154	9%	444	27%	246	15%	471	28%	43	3%	313	19%	1,671	100%

Acronyms: Abi = Abiraterone; Apa = Apalutamide; Doce = Docetaxel; Enza = Enzalutamide; Daro = Darolutamide; Daro+Doce = Darolutamide+Docetaxel.
*5 months data.

Table A2. Number of men diagnosed with prostate cancer in England between 1st January 2019 and 31st December 2025 captured in the Rapid Cancer Registration Dataset.

Year	Number of men diagnosed
2019	43,616
2020	33,076
2021	39,920
2022	50,051
2023	53,583
2024	57,029
2025	60,827

Table A3. Number of men diagnosed with prostate cancer in Wales during 2021-2024.

Year	Number of men diagnosed
2021	1,996
2022	2,551
2023	2,402
2024	2,700

Table A4. Number of men who received radical prostatectomies in England during 2019-2025.

Year	Number of men who received radical prostatectomies
2019	7,186
2020	5,586
2021	5,821
2022	7,377
2023	8,500
2024	9,552
2025	10,218

Table A5. Number of men who received radical prostate radiotherapy in England between 1st January 2019 and 31st October 2025.

Year	Number of men who received radical prostate radiotherapy
2019	13,690
2020	12,161
2021	12,006
2022	14,865
2023	18,453
2024	20,712
2025*	17,933
* 10 months data	

Table A6. Number of men who received radical prostatectomies in Wales during 2021-2024.

Year	Number of men who received radical prostatectomies
2021*	228
2022*	255
2023*	315
2024^	245
*For 2021-2023, results are the number of radical prostatectomies conducted in the respective year. ^The number of men diagnosed in 2024 having radical prostatectomy, surgery could be in a later year. The interpretation has changed as the format of the data we receive from our data provider has changed.	

Table A7. Number of men who received radical prostate radiotherapy in Wales during 2021-2024.

Year	Number of men who received radical prostatectomies
2021*	664
2022*	830
2023*	935
2024^	606
*For 2021-2023, results are the number of men who received radical prostate radiotherapy in the respective year. ^The number of men diagnosed in 2024 having radical prostate radiotherapy, radiotherapy could be in a later year. The interpretation has changed as the format of the data we receive from our data provider has changed.	

Table A8. The number of men starting different types of radiotherapy in England, from 1st January 2019 to 31st October 2025.

	Conventional		Hypo-fractionated 49-61Gy in up to 20 fractions		Ultra-hypofractionated 34.1-37.9Gy in 6 fractions (including 36Gy/6 fractions)		SBRT 35-50Gy in 5 fractions (including 36.25Gy/5 fractions)*		Total	
2019	2,823	22%	9,864	77%	84	<1%	44	<1%	12,815	100%
2020	1,897	17%	8,993	81%	116	1%	164	1%	11,170	100%
2021	1,477	14%	8,814	81%	134	1%	452	4%	10,877	100%
2022	1,707	13%	11,067	82%	164	1%	556	4%	13,494	100%
2023	1,720	10%	14,054	84%	98	1%	953	6%	16,825	100%
2024	1,297	7%	16,189	85%	133	1%	1,451	8%	19,070	100%
2025#	521	3%	13,982	84%	231	1%	1,845	11%	16,579	100%

Acronyms: Gy = Gray; SBRT = Stereotactic Body Radiation Therapy.

*Likely under-reported, for further investigation.

#10 months data.

Table A9. Data completeness for men diagnosed with prostate cancer in England during 2023 captured in the National Cancer Registration Dataset.

Data item	Percentage of men with data item complete
Ethnicity	94%
Deprivation	100%
Performance status	72%
PSA	62%
Gleason score	82%
TNM (all complete)	79%

Table A10. Data completeness for men diagnosed with prostate cancer in Wales in 2024.

Data item	Percentage of men with data item complete
Ethnicity	30%
Deprivation	99%
Performance status	95%
PSA	98%
Gleason score	54%
TNM (all complete)	76%

Table A11. Patient and diagnostic characteristics for men newly diagnosed with prostate cancer in England during 2023 and in Wales during 2024.

Data variable	England		Wales	
	N	%	N	%
<i>Time period covered</i>	<i>1Jan – 31Dec2023</i>		<i>1Jan-31Dec2024</i>	
No. of men with new diagnosis of prostate cancer	57,444		2,700	
Age				
<60	7,810	14%	295	11%
60-69	19,092	33%	841	31%
70-79	22,466	39%	1,142	42%
≥80	8,076	14%	422	16%
Total	57,444	100%	2,700	100%
Missing	0	(0%)	0	(0%)
Ethnicity				
Asian or Asian British	1,398	3%	<5	<1%
Black, Black British, Caribbean or African	2,933	5%	0	0%
Mixed or multiple ethnic groups	412	1%	<5	<1%
White	48,148	89%	803	99%
Other	1,101	2%	<5	<1%
Total	53,992	100%	810	100%
Missing	3,452	(6%)	1,890	(70%)
Indices of multiple deprivation (IMD) of LSOA				
1 (least deprived)	14,222	25%	584	22%
2	13,452	23%	636	24%
3	12,108	21%	569	21%
4	9,914	17%	516	19%
5 (most deprived)	7,748	13%	372	14%
Total	57,444	100%	2,677	100%
Missing	0	(0%)	23	(1%)
Performance status				
0	30,319	74%	1,405	55%
1-2	10,153	25%	1,095	43%
≥3	721	2%	52	2%
Total	41,193	100%	2,552	100%
Missing	16,251	(28%)	148	(5%)
Charlson score				
0	41,395	72%	1,151	75%
1	10,605	18%	255	17%
≥2	5,444	9%	136	9%
Total	57,444	100%	1,542	100%
Missing	0	(0%)	1,158	(43%)
Prostate Specific Antigen (PSA)				
<10	18,458	52%	1,157	44%
10-19	7,432	21%	666	25%
≥20	9,739	27%	823	31%
Total	35,629	100%	2,646	100%
Missing	21,815	(38%)	54	(2%)
Gleason score				
6	8,503	18%	431	29%



7	26,317	56%	664	45%
≥8	12,181	26%	369	25%
Total	47,001	100%	1,464	100%
<i>Missing</i>	<i>10,443</i>	<i>(18%)</i>	<i>1,236</i>	<i>(46%)</i>
T stage				
T1	3,522	7%	129	5%
T2	25,041	51%	1,285	53%
T3	17,748	36%	758	31%
T4	2,361	5%	242	10%
Total	48,672	100%	2,414	100%
<i>Missing</i>	<i>8,772</i>	<i>(15%)</i>	<i>286</i>	<i>(11%)</i>
N stage				
N0	43,040	89%	1,935	83%
N1	5,251	11%	409	17%
Total	48,291	100%	2,344	100%
<i>Missing</i>	<i>9,153</i>	<i>(16%)</i>	<i>356</i>	<i>(13%)</i>
M stage				
M0	41,798	87%	1,776	80%
M1	6,312	13%	444	20%
Total	48,110	100%	2,220	100%
<i>Missing</i>	<i>9,334</i>	<i>(16%)</i>	<i>480</i>	<i>(18%)</i>
Risk group*				
Low risk	6,000	12%	262	12%
Intermediate	16,626	34%	620	29%
High-risk/locally advanced	20,296	41%	829	38%
Metastatic	6,312	13%	444	21%
Total	49,234	100%	2,155	100%
<i>Insufficient</i>	<i>8,210</i>	<i>(14%)</i>	<i>545</i>	<i>(20%)</i>
Cambridge Prognostic Group (CPG)				
CPG1	7,031	18%	627	30%
CPG2	6,781	17%	238	11%
CPG3	3,873	10%	175	8%
CPG4	5,915	15%	216	10%
CPG5	7,811	20%	303	14%
N1	2,191	5%	122	6%
M1	6,312	16%	444	21%
Total	39,914	100%	2,125	100%
<i>Insufficient</i>	<i>17,530</i>	<i>(31%)</i>	<i>575</i>	<i>(21%)</i>
Acronyms: PSA = Prostate Specific Antigen; TNM = Tumour, Nodes, Metastases Classification of Malignant Tumours; RCRD = Rapid Cancer Registration Dataset. N1 = Nodes/Nodal disease. M1 = metastatic disease. *unadjusted values.				

Table A12. Treatment characteristics for men receiving radical radiotherapy or prostatectomy in England during 2025 and in Wales during 2024.

During 2025 and in Wales during 2024:

Data variable	England*		Wales**	
	N	%	N	%
Time period covered	1 Jan 2025 – 31 Dec 2025		1 Jan 2024 - 31 Dec 2024	
Radical prostatectomy information				
No. of men undergoing radical prostatectomy	10,218		245	
Prostatectomy type				
Robotic	10,061	98%	165	86%
Laparoscopic	76	1%	20	10%
Open	81	1%	7	4%
Total	10,218	100%	192	100%
Missing	0	(0%)	53	(22%)
Lymphadenectomy performed				
No	9,094	89%	148	84%
Yes	1,124	11%	29	16%
Total	10,218	100%	177	100%
Missing	0	(0%)	68	(28%)
Radical radiotherapy information				
No. of men undergoing radical radiotherapy	17,933^		606	
Radiotherapy modality				
Intensity Modulated Radiation Therapy	17,171	96%	339	100%
3D conformal	762	4%	0	%
Total	17,933	100%	339	100%
Missing	0	(0%)	267	(44%)
Planned radiotherapy region				
Prostate and/or seminal vesicles	13,284	75%	264	63%
Whole pelvis incl. lymph nodes	4,325	25%	156	37%
Total	17,609	100%	420	100%
Missing	324	(2%)	186	(31%)
*For England, results are treatments (surgery or radiotherapy) that were conducted in 2025. **For Wales, results are for men diagnosed in 2024, treatments (surgery or radiotherapy) could be in a later year. The interpretation is different between England and Wales as the format of the data we receive from respective data providers is different.				
^10 months data				